Pharmaceutical Network June 23 News In the early 2016，Treatment of rare diseased hypertension import targeted drugs & ldquo; Quan Keli & rdquo; active price reduction 80%，From 199.8 million per box to 3996 yuan per box，Not only becoming the most price -decline medicine，It also broke the patented patented medicine & ldquo; noble medicine & rdquo;，The iconic event of becoming the Chinese pharmaceutical market，More multinational pharmaceutical companies are walking on the road to significant price reductions。

 

  In fact, how does multinational pharmaceutical companies perform in China?

 

  According to the situation published by major foreign pharmaceutical companies，2015 Sailori sales in China achieved a 20%growth，Pfizer has achieved 10%growth，Merhadon achieved 8%sales growth in 2015。Lilly Lilly annual sales increased by 2%。The performance is good or bad，Judging from the 10 pharmaceutical companies selling the sales of multinational pharmaceutical companies in China，The growth rate of sales is mainly concentrated at 5%-10%。This is basically in line with 7.6%of the annual pharmaceutical terminal sales released by Zhongkang Information before。

 

  From the perspective of domestic drug terminal sales，Foreign -funded pharmaceutical companies are still stable in sales in China，In the 2015 Pharmaceutical Industry Rankings released by Zhongkang Information，There are as many as 20 foreign pharmaceutical companies in the top 100。Among them, there are 4 top ten in the top ten。Pfizer Pharmaceutical is as high as 31.3 billion yuan at annual sales (calculated at terminal retail price)，top list。

 

stake sports betting app

　　

  Data Source: Zhongkang CMH，Sales are calculated at terminal retail price

 

  Over the years，Foreign -funded pharmaceutical companies with the original pricing advantage of the original drug，Sales momentum of sales in major large cities in China。Compared with，Innovative drugs from foreign pharmaceutical companies are not dazzling in China，This is low with the domestic average consumption level、The medical insurance payment system has a great relationship。

 

  It is understood，In China，60-70 patented drugs used clinically and 150-160 patents expired but unsatisfactory exclusive medicine，Most of them belong to foreign pharmaceutical companies。Study shows，Innovative drugs in the highest retail price in China，One third is higher than the international public price。This advantage has been maintained for stake online sports bettingStake Sports Bettingmany years，But in the context of domestic medical insurance control fees，The original strategic model of foreign pharmaceutical companies encountered a bottleneck。This growth rate of foreign pharmaceutical companies in China has declined year by year in China。

 

  Compared to domestic companies，Despite the 2013 bribery incident、2014 layoff storm，and the large -scale abandonment incident in 2015，The overall development of foreign pharmaceutical companies is still relatively stable。In addition to GSK performance, there is a large fluctuations，Other foreign companies are still moisturizing in China。

 

  but，This year's situation is different from the past，There are many original research products of pharmaceutical companies，A sharp price reduction by actively or negotiating，This pharmaceutical company that reduces price reductions may cause impact，One aspect，The details of the national medical insurance control fee are implemented in place，The consistency evaluation of generic drugs in China is getting close to，More and more high -quality generic drug competition，A large number of original drug research drugs have only one layer of paper distance。

 

  Of course，In order to cope with the impact of the decline in the sales of the original drug，In addition to reducing the price and change market，Many foreign pharmaceutical companies have adjusted China's market strategy，Including channel transfer、Accelerate the introduction of new drugs and develop local mergers and acquisitions。

 

  Price strategy: price reduction and market

 

  According to incomplete statistics，The China Development and Reform Commission has lowered the price of drugs nearly 30 times，But every time the original medicine is not injured。This is the factor of protection of related policies，There are also factors related to the lagness of the consistency evaluation of generic drugs in most domestic enterprises。

 

  The turning point of the original research drug reduction price reduction is after the Glangoscosk incident，Compliance pressure increased by foreign pharmaceutical companies，Pharmaceutical companies themselves also feel the unsustainable of this model。But the market environment has not completely changed，Foreign -funded pharmaceutical companies relative to their local competitors，Under the limit of compliance，Stress Mountain Big。

 

  With the pressure of medical insurance funds, more and more，In recent years, the state's control of hospital drug costs has become more and more stringent，Including the regulations of the State Council in 2017, the proportion of public hospitals in public hospitals does not exceed 30%，All kinds of auxiliary medications、High -priced drugs and traditional Chinese medicine injections are strictly monitored。In addition，The market has also called for the cancellation of the original pricing of the original drug，As early。

 

  2016 foreign price reduction medicine

 

  July 2015，Grammomsk announced to the outside world，Price reduction of its 3 hepatitis B antiviral drugs，The price reduction is 20-30%，This news has aroused the attention and heated discussion of the price of drug prices in multinational pharmaceutical companies。As early as May last year，The National Development and Reform Commission and other departments jointly issued the "Notice Stake Sports Bettingon stake online sports bettingPromoting Opinions on Promoting Pharmaceutical Price"，At the same month of the National Health and Family Planning Commission, the "Pilot Work Plan for Establishing a Pharmaceutical Price Negotiation Mechanism"，This means，Reform of the pricing method，It will master multinational pharmaceutical companies that master the vast majority of original drugs，Bring great pressure。

 

  At the end of last year，Pulmonary hypertension therapy pills developed by Ai Keetaron Company，From January 1, 2016, it will be reduced from 19980 yuan/box to 3998 yuan/box (specification is 125mg*56 tablets/box)，The price reduction is 80%。Before the domestic generic drugs have not been launched，Ai Keetaron actively reduces the price sharply，On the one hand, I hope to enter the national medical insurance directory，On the other hand, it can also be before the imitation drugs are not available，See the main market share。Can be described as two birds with one stone。

 

  and the three major diseases announced this year's medication negotiation price negotiation price reduction，Among them, Astraik's Gefitinib、Verade of GlaxoSmith is all from foreign research medicines，From the perspective of price reduction among the price reduction，The two pharmaceutical companies can be said，decreased 55%respectively，67%。The result of this negotiation is just the beginning，In the future, there are more companies to follow up。

 

  but，Foreign -funded enterprises reduced prices for sales，Past experience prompts the lower the price of the medicine, the less sales, the better，It is still yet to be confirmed whether the sales of drug prices can be greatly driven.。Current，Many pharmaceutical companies are still watching。The policy is not clear before，Pressing the soldiers is the choice of most companies，Of course, there are also multinational pharmaceutical companies say，Patent expiration will not reduce prices，It will use a strategy that stops production from generic drugs instead。

 

  Channel Strategy: Sinking channels

 

  Under the current medical reform，Dual pressures of foreign pharmaceutical companies are facing the decline in prescription drug prices and restrictions on compliance restrictions，It is difficult to avoid the trend of decline in revenue in the revenue of prescription drugs。Before the market has not entered the virtuous cycle that can enter the drug and service,，Foreign -funded pharmaceutical companies will have to find a new way，Make up for the decline in revenue in the market's market revenue。

 

  From the perspective of market access，Foreign -funded pharmaceutical companies' main markets over the years are still urban -level hospitals，In recent years，The growth rate of urban -level hospitals has been significantly behind retail pharmacies and county -level hospitals、City Grassroots Hospital。The 2015 China Pharmaceutical Market Report released by Zhongkang CMH before，Pharmaceutical sales growth rate of urban -level hospitals in 2015 5.8%，and retail pharmacy increased by 11.6%year -on -year，County Grade Hospital and City Grassroots Hospitals increased by 11.1%and 9.7%, respectively。

 

  Although foreign -funded pharmaceutical companies have accumulated a certain academic resource in the level hospitals in major cities，But in retail pharmacies、The resources of the city grassroots hospitals and county -level hospitals stake sports betting appStake Sports Bettingare relatively weak。In the context of the national advocating graded diagnosis and treatment，The sales of grassroots hospitals and retail pharmacies are expected to undertake prescriptions of outflow of some cities -level hospitals，This has also formed a certain attraction to foreign -funded enterprises。

 

  Actually，Five or six years ago, including Pfizer、Merck and other companies have tried the operation of the grass -roots market，Even a grass -roots team，But the overall effect is not good，Several reasons caused，First, the size of the grass -roots market is still small，Second is the fierce competition in domestic enterprises，Third, the difficulty of market operation is too high。But now the market environment has changed a lot，This change has effectively improved the attractiveness of the grassroots。

 

  December 2014，Astrikan announced，Chinese local professional manager Wang Lei became the president of Mainland China and Hong Kong。His key task is to expand the grass -roots medical market，For this，2015初，Astrikang specially established a county hospital team located under the Ministry of Commerce，Responsible for business channel development。

 

  2015，Sanofi also listed the coverage of the county -level hospital market as its annual strategic focus。According to the information published by Long Xianli, senior vice president of Sanofi Asia，At present, Sanofi has covered 1500 counties，and owns more than 1,000 staff。

 

  and companies such as Merck and Pfizer and other companies have chosen to increase market investment in retail pharmacies，Merhadon Company set up a development team for retail pharmacies。Always，Foreign pharmaceutical companies' positioning of retail pharmacies is the marketing terminal of the OTC brand，But as the prescription drug is weak in sales in the courtyard，More enterprises also use retail pharmacies as a terminal training for prescription drug sales。

 

  Product Strategy: Accelerate the introduction of new drugs

 

  Overall，New drugs from multinational pharmaceutical companies are not optimistic in China，As described above，and the medical reimbursement limit is limited，and the medical reimbursement limit is limited，and new drugs are generally high。But looking at the global research and development field，Innovation of drugs，Especially for tumors that have not met clinical needs、Innovative drugs in the fields of diabetes and other fields，It has always been a hot spot chased by pharmaceutical companies，and the Chinese market needs strong demand for these heavy fields。

 

  It is understood，At present, the new drugs of foreign pharmaceutical companies account for more than 80%of all listed and innovative drugs in the Chinese market during the same period。In recent years，Innovation of domestic enterprises has accelerated，At the same time，The pace of inter -national pharmaceutical enterprises is accelerating the listing of original innovative drugs in China。19 of the 19 varieties that are intended to be included in the priority review procedure and drug registration recently announced，12 are declared by foreign pharmaceutical companies。

 

  Over the years，The pace of the original innovative drugs of foreign pharmaceutical companies entering the stake sports betting appStake Sports Bettingcountry is slow，This has a lot to do with the slowest progress of my country's drug registration and approval，But since last year，Domestic drug approval and registration under the reform of major reforms，Future drug registration review acceleration is obvious。Considering that the sales of the original drug sales are weak、New channel expansion difficulties，Accelerating the introduction of new drugs has become one of the choices of many multinational pharmaceutical companies。

 

  More and more foreign -funded enterprises that see Chinese research capabilities，Big multinational pharmaceutical giants are trying to develop new drugs in Chinese laboratories，or set up a research and development center in China。

 

  At the beginning of this month，Nuohua, a multinational pharmaceutical company invested $ 1 billion、The R & D park constructed in Shanghai officially publicly debuted。It is understood，Nuohua Shanghai R & D Park's new drug research and development project is mainly targeted at high incidence of high incidence in China and Asia，1 is the field of cancer，Including lung cancer、Liver cancer、Stomach cancer and nasopharyngeal cancer; second, the field of liver disease，Including liver fibrosis caused by chronic hepatitis、liver cirrhosis and non -alcoholic fatty liver disease。Current，More than a thousand employees work here，Among them, about 600 R & D personnel。

 

  Lilly Lili、Astrikan、Roche、Bayer、Merhado、Merkees Shelanino and other large multinational pharmaceutical companies have also been in Beijing as early as Beijing、Shanghai and other places have established new drug research and development centers。